Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | TACR1 | P25103 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.39 |
| ▸ | BRD1 | O95696 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631025 | 0.89 | HTR2C (0.51) | HTR2CHTR2BHTR2ABRPF1BRD1 | |
| SCHEMBL5632322 | 0.89 | HTR2C (0.51) | HTR2CHTR2BHTR2ABRPF1BRD1 | |
| SCHEMBL5631031 | 0.89 | HTR2C (0.51) | HTR2CHTR2BHTR2ABRPF1BRD1 | |
| Hydrochloric Acid SCHEMBL5632297 | 0.87 | HTR2C (0.50) | HTR2CHTR2BHTR2ABRPF1BRD1 | |
| Hydrochloric Acid SCHEMBL5632287 | 0.87 | HTR2C (0.50) | HTR2CHTR2BHTR2ABRPF1BRD1 | |
| Trifluoroacetic Acid SCHEMBL5632214 | 0.82 | RAD52 (0.44) | HTR2CHTR2ACYP3A4RAD52 | |
| Trifluoroacetic Acid SCHEMBL5633122 | 0.80 | PKM (0.40) | HTR2CHTR2BHTR2ACYP3A4RAD52 | |
| Trifluoroacetic Acid SCHEMBL5631915 | 0.80 | PKM (0.40) | HTR2CHTR2BHTR2ACYP3A4RAD52 | |
| Trifluoroacetic Acid SCHEMBL5631791 | 0.79 | HTR2C (0.43) | HTR2CHTR2BHTR2ARAD52 | |
| SCHEMBL4884026 | 0.79 | HTR7 (0.42) | HTR2CHTR2BHTR2ABRPF1BRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885TACR1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.